Eric Haura,
M.D.
Associate Professor in Oncology and Medicine
Member-in-Residence of the Moffitt Cancer Center
E-mail: Eric.Haura@moffitt.org
Phone: (813)745-6827
Training
Research Fellow: Department of Genetics, Laboratory of Dr. Joseph Nevins, Duke University Medical Center, October 1998 to June 2000.
Clinical Fellow: Hematology and Oncology, Duke University Medical Center, July 1997 to June 2000.
Residency: Internal Medicine, The Johns Hopkins Hospital, July 1994 to June 1997.
M.D.: Duke University School of Medicine, 1990 to 1994.
B.S.: Biomedical Engineering, The Johns Hopkins University, 1986 to 1990.
Research
Interests
Our laboratory is interested in oncogenic signal transduction pathways involved in the pathogenesis of lung cancer. The major focus of the lab has been on understanding the role of tyrosine kinase pathways and STAT signaling in lung cancer.
Ongoing projects include (1) characterizing the ability of novel inhibitors of EGFR, Src-family kinases, andStat3 signaling to suppress lung cancer cell growth with accompanying evaluation of downstream signaling pathways, (2) characterizing Stat3 and Stat1 gene expression profiles using Affymetrix gene arrays, (3) development of lung-specific Stat3 knockout mice to evaluate the requirement of Stat3 in tumor initiation and promotion, (4) determining a role for Stat3 signaling in tumor cell invasion/metastasis by examining a direct role of Stat3 in controlling genes involved in cell invasion,
Our lab also has available lung cancer tumors specimens for translational studies. This includes a tissue microarray consisting of approximately 250 NSCLC specimens with accompanying clinical data available for studies evaluating the role of various signaling pathways, a collection of tumor RNA with accompanying clinical data to evaluate prognostic roles of genes, and a collection of fresh frozen specimens available for molecular assays.
Search
for publications by: 
This
search will be conducted at the US National Library of Medicine (NLM) and PubMed.
Selected Publications
Daniel J. Dauer ,Bernadette Ferraro, Lanxi Song, Bin Yu, Linda Mora, Ralf Buettner, Steve Enkemann, Richard Jove, and Eric B. Haura . Regulation of genes common to both wound healing and cancer by Stat3. Accepted for publication with minor revisions, Oncogene, 2004.
Zhong Zheng, Gerold Bepler, Alan Cantor, and Eric B. Haura . Small tumor size and limited smoking history predicts activated EGFR in early stage non-small cell lung cancer. Accepted for publication, Chest, 2004.
Ferraro, B., Bepler, G., Sharma, S., Cantor, A., and Haura, E.B. Egr1 predicts PTEN and overall survival in patients with non-small cell lung cancer. Accepted for publication, J Clin Oncol., 2004 .
Scott N. Freeman, Gerold Bepler, Eric Haura, Rebecca Sutphen and W. Douglas Cress. Common MCL-1 Promoter Polymorphisms.Accepted for publication, JNCI, 2004.
Alberto Chiappori, George Simon, Charles Williams, Eric Haura, Caio Rocha-Lima, Henry Wagner, Gerold Bepler, Scott Antonia . Phase II Study of First Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer. In Press, Oncology, 2004.
Gerold Bepler, Zhong Zheng, Ashish Gautam, , Swati Sharma, Alan Cantor, Anupama Sharma, Douglas Cress, Young-Chul Kim, Rafael Rosell, Colleen McBrdie, Lary Robinson, Eric Sommers, and Eric Haura. Ribonucleotide reductase M1 gene promoter polymorphisms, activity, and survival in patients with non-small cell lung cancer. In Press, Lung Cancer, 2004.
Brandon A. Howard, Zhong Zheng, Michael J. Campa, Michael Z. Wang, Anupama Sharma, Eric Haura, James E. Herndon II, Michael C. Fitzgerald, Gerold Bepler, Edward F. Patz, . Translating Biomarkers into Clinical Practice: Prognostic Implications of Cyclophilin A and Macrophage Migratory Inhibitory Factor Identified from Protein Expression Profiles in Non-Small Cell Lung Cancer.Lung Cancer. 2004 Dec;46(3):313-23.
Haura EB , Cress WD, Chellappan S, Zheng, Z. and Bepler G. Anti-apoptotic Signaling Pathways in Non-Small Cell Lung Cancer: Biology and Therapeutic Strategies.Clin Lung Cancer. 2004 Sep;6(2):113-22.
Gerold Bepler, Swati Sharma, Alan Cantor, Ashish Gautam, Eric Haura, George Simon, Anupama Sharma, Eric Sommers, and Lary Robinson. Discovery and Validation of RRM1 and PTEN as Prognostic Parameters for Survival in Patients with Non-Small Cell Lung Cancer . J Clin Oncol. 2004 May 15;22(10):1878-85.
D’Amato, G., Rocha Lima, C., Muro-Cacho, C., and Haura, E.B. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer. 2004 Jun;44(3):381-90.
Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther . 2004 Mar;3(3):261-269.
Hauser, P., Ma, L., Agrawal, D., Haura, E.B., Cress, W.D., and Pledger, W.J. Efficient down-regulation of cyclin A-associated activity and expression in suspended primary keratinocytes requires p21 cip1 .Mol Cancer Res. 2004 Feb;2(2):96-104.
Cancer Biology Ph.D. Program
H. Lee Moffitt Cancer Center, MRC-4 East
12902 Magnolia Drive
Tampa, Florida 33612
Phone: 813-745-6876
E-mail: CancerPHD@moffitt.org
Copyright © 2000 University of South Florida